CN106690327A - Mixed probiotic tablets and low-temperature coating preparation method thereof - Google Patents
Mixed probiotic tablets and low-temperature coating preparation method thereof Download PDFInfo
- Publication number
- CN106690327A CN106690327A CN201611077462.9A CN201611077462A CN106690327A CN 106690327 A CN106690327 A CN 106690327A CN 201611077462 A CN201611077462 A CN 201611077462A CN 106690327 A CN106690327 A CN 106690327A
- Authority
- CN
- China
- Prior art keywords
- parts
- lactobacillus
- tablet
- probiotics
- microbial inoculums
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 145
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 145
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 78
- 238000002360 preparation method Methods 0.000 title claims abstract description 29
- 239000011248 coating agent Substances 0.000 title claims abstract description 22
- 238000000576 coating method Methods 0.000 title claims abstract description 22
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 51
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 50
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 50
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 46
- 241000894006 Bacteria Species 0.000 claims abstract description 45
- 244000199866 Lactobacillus casei Species 0.000 claims abstract description 45
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 45
- 235000013958 Lactobacillus casei Nutrition 0.000 claims abstract description 44
- 229940017800 lactobacillus casei Drugs 0.000 claims abstract description 44
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 44
- 238000000034 method Methods 0.000 claims abstract description 16
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 13
- 239000002068 microbial inoculum Substances 0.000 claims description 92
- 238000002156 mixing Methods 0.000 claims description 46
- 241001134770 Bifidobacterium animalis Species 0.000 claims description 39
- 229940118852 bifidobacterium animalis Drugs 0.000 claims description 39
- 150000001875 compounds Chemical class 0.000 claims description 32
- 239000012530 fluid Substances 0.000 claims description 21
- 244000068988 Glycine max Species 0.000 claims description 20
- 235000010469 Glycine max Nutrition 0.000 claims description 20
- 229920001282 polysaccharide Polymers 0.000 claims description 20
- 239000005017 polysaccharide Substances 0.000 claims description 20
- 239000002994 raw material Substances 0.000 claims description 20
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 claims description 19
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 19
- 239000008103 glucose Substances 0.000 claims description 19
- 150000004676 glycans Chemical class 0.000 claims description 19
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 18
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 18
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 18
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 18
- 238000000855 fermentation Methods 0.000 claims description 16
- 230000004151 fermentation Effects 0.000 claims description 16
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 15
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 15
- 238000004806 packaging method and process Methods 0.000 claims description 10
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 9
- 235000001727 glucose Nutrition 0.000 claims description 8
- 238000010348 incorporation Methods 0.000 claims description 8
- 238000005119 centrifugation Methods 0.000 claims description 7
- 239000000725 suspension Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000002054 inoculum Substances 0.000 claims description 5
- 239000003223 protective agent Substances 0.000 claims description 5
- 241000196324 Embryophyta Species 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- 210000000481 breast Anatomy 0.000 claims description 3
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical compound CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- 239000001963 growth medium Substances 0.000 claims description 3
- SCVOEYLBXCPATR-UHFFFAOYSA-L manganese(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Mn+2].[O-]S([O-])(=O)=O SCVOEYLBXCPATR-UHFFFAOYSA-L 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 239000011814 protection agent Substances 0.000 claims description 3
- 230000007420 reactivation Effects 0.000 claims description 3
- 235000020183 skimmed milk Nutrition 0.000 claims description 3
- 238000009423 ventilation Methods 0.000 claims description 3
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 2
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 claims description 2
- 241000186660 Lactobacillus Species 0.000 claims 3
- 229940039696 lactobacillus Drugs 0.000 claims 3
- 235000013351 cheese Nutrition 0.000 claims 2
- 240000000111 Saccharum officinarum Species 0.000 claims 1
- 235000007201 Saccharum officinarum Nutrition 0.000 claims 1
- 229940009289 bifidobacterium lactis Drugs 0.000 claims 1
- 238000011081 inoculation Methods 0.000 claims 1
- -1 polysaccharide compound Chemical class 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 abstract description 7
- 239000000843 powder Substances 0.000 abstract description 6
- 238000003860 storage Methods 0.000 abstract description 4
- 230000036039 immunity Effects 0.000 abstract description 3
- 230000001079 digestive effect Effects 0.000 abstract description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 abstract description 2
- 230000000813 microbial effect Effects 0.000 abstract description 2
- 241001205141 Bifidobacterium animalis subsp. lactis V9 Species 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- 244000005700 microbiome Species 0.000 description 9
- 238000004321 preservation Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 241000186000 Bifidobacterium Species 0.000 description 4
- 230000003042 antagnostic effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000186781 Listeria Species 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 241000607768 Shigella Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 235000015141 kefir Nutrition 0.000 description 2
- 235000015138 kumis Nutrition 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101100174180 Caenorhabditis elegans fos-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 241000261145 bacterium 3.5 Species 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/125—Casei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/515—Animalis
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses mixed probiotic tablets and a low-temperature coating preparation method thereof and belongs to the field of probiotic tablets. The mixed probiotic tablets are prepared from 2-7 parts of a lactobacillus acidophilus KT-A1 agent, 2-7 parts of a lactobacillus casei Zhang agent, 2-7 parts of a bifidobacterium animalis subsp. lactis V9 agent and 2-7 parts of a lactobacillus plantarum P-8 agent with a low-temperature coating technology. According to the probiotic tablets prepared with the method, bacterium loss of probiotics in a tablet preparation process is avoided, after the tablets are stored for 5 months at the temperature of 37 DEG C, the total viable count of probiotics in the product keeps not lower than 5*10<9> CFU/g; furthermore, storage stability of the probiotics in the shelf life of the product is greatly improved, weight of each tablet is 0.7-0.9 g, the hardness reaches 7 N/cm<2> or higher, the surface is smooth, and the phenomenon of powder falling is avoided. Besides, the mixed probiotic tablets have excellent resistance to gastrointestinal digestive juice, improve capacity of intestinal microbial community structure of a human body and have a regulating function for body immunity.
Description
Technical field
The invention belongs to probiotic tablet field, and in particular to one kind mixing probiotic tablet and its low temperature are coated preparation side
Method.
Background technology
Probiotics is defined as " microorganism that intake sufficient amount can provide host the work of beneficial effect ".Probiotics has
There are different physiological roles, including improve human body intestinal canal function, suppress harmful bacteria growing, reduce intestines problem, alleviate lactose intolerance
Disease, the absorption for promoting the nutriments such as sugared, protein and calcium, magnesium, norcholesterol, regulation immune system, antitumor, pre- anti-cancer
Deng.But want to obtain beneficial function, it is desirable to which probiotics all keeps activity and metabolic stability in product and host, and reaches certain
Quantity (is commonly referred to be in every gram or milliliter product and is not less than 107CFU).However, during production, storage, transport etc., benefit
Raw bacterium will be by food component (acid, oxygen, additive etc.), storage temperature and Host Digestion system (hydrochloric acid in gastric juice, cholate, enzyme) etc.
Influence, often result in viable count and decline to a great extent, the viable count being finally colonized in enteron aisle less than can play in theory physiology work
Minimum value.
The patent of invention of Application No. 200910253872.8 discloses " a kind of probiotic tablet and preparation method thereof ", its
It is characterized as with glucose, lactose, micro- product cellulose etc. as raw material prepares particle, remixes active ingredient probiotics powder and tristearin
Sour magnesium carries out compressing tablet.The advantage of the invention is:The probiotic tablet of preparation is high because of its Viable detection, convenient to take, is easy to
Absorb, therapeutic effect is obvious.
The patent of invention of Application No. 201410129017.7 discloses " a kind of probiotics micro-ecological tablet and its preparation side
Method ", it is characterized by probiotics micro-ecological tablet is probiotics bacterium powder 90%~98% by mass, FOS 1%~9%,
Magnesium stearate 0.1%~1%.Preparation is to be activated Bifidobacterium, and prepares Kefir fermenting agent;It is again that the two is blended
Fermentation, low temperature concentrate drying, batch mixing compressing tablet are obtained.Mixed fermentation is to be inoculated with probiotics mixed bacteria, 28~36 DEG C of bars
Fermented 16~24 hours under part, the ratio 1~3 of Kefir fermenting agent and Bifidobacterium in mixed bacteria:1.The present invention will open phenanthrene
That leavening and Bifidobacterium carry out high density mixed fermentation, and strain is various, stable storing, and the viable count in tablet is respectively reached
2000000000 more than cfu/g;Digestion power can be not only improved, while also enhancing colonization ability of the probiotics in enteron aisle;Have
It is of high nutritive value, the features such as unique flavor.
The patent of invention of Application No. 201410709383.X discloses " a kind of probiotics micro-ecological tablet and its preparation
Method ", it is characterized by with probiotics powder agents such as Lactobacillus plantarums as primary raw material, the composite modified dietary fiber of science, fruit vegetable powder,
Oligosaccharide, plant extracts, albumen powder, tea extract, Chinese herbal medicine extract etc., improve has real meaning to beneficial flora
The content of the soluble cellulose of justice, enhances the physiologically active of cellulose, and then increasing beneficial bacteria of intestinal tract flora species
Meanwhile, endogenous and colonization ability and resident time of the external source probio in human body intestinal canal is significantly enhanced, effectively inhibit intestines
The growth and breeding of road harmful bacteria especially Gram-negative bacteria, fully have adjusted the composition of beneficial bacteria of intestinal tract flora, preparation
Probiotic tablet bioactivity is high, human body intestinal canal resident time it is long, fat-reducing effect is notable and suitable population is extensive.
But to sum up, because probiotic tablet is a kind of product easy to carry, containing high concentration number of live bacteria of probiotics, because of benefit
The survival stability of raw bacterium is highly prone to the influence of reserve temperature, and probiotic tablet in the market can not be realized in normal temperature
Lower storage, and the probiotic tablet rough surface for producing, the easy dry linting of phase mutual friction, has a strong impact on product in transportation
It is attractive in appearance.
Therefore, the present invention is prepared for a kind of mixing probiotic tablet, and avoiding probiotics bacterial by new technological means
Storage-stable of the probiotics in shelf life is improved while being caused damage in preparation process.Mixing benefit is improved simultaneously
The added value of raw bacterium tablet, and its tolerance in body, keep vigor higher, while being digested and assimilated body is improved
Rate, improves body gastrointestinal tract environment, adjusts immunity of organism, and effectively prevention is alleviated the aspects such as diarrhoea and further optimized.
The content of the invention
Technical problem solved by the invention be overcome it is above-mentioned in the prior art mixing probiotic tablet preparation process with
And in shelf life the prebiotic easily damaged mistake of microbial activity defect, while improve mixing probiotic tablet added value, carry
Mix bacterium agent high keeps vigor higher in the tolerance of body, while improving body digestibility, improves body stomach and intestine
Road environment, adjusts immunity of organism, and effectively the aspects such as diarrhoea are alleviated in prevention significant effect.
In order to achieve the above object, the present invention uses following technical scheme:
One kind mixing probiotic tablet, is mainly prepared by the raw material of following parts by weight:Lactobacillus acidophilus KT-A1 microbial inoculums 2-
7 parts, 2-7 parts of Lactobacillus casei Zhang microbial inoculum, 2-7 parts of bifidobacterium animalis subspecies V9 microbial inoculums, Lactobacillus plantarum P-8 microbial inoculums
2-7 parts, galactooligosaccharide 10-40 parts, glucose 10-30 parts, microcrystalline cellulose 10-30 parts, soluble soybean polysaccharide 0.1-0.7
Part.
Preferably, the mixing probiotic tablet, is mainly prepared by the raw material of following parts by weight:Lactobacillus acidophilus KT-
2-5 parts of A1 microbial inoculums, 2-5 parts of Lactobacillus casei Zhang microbial inoculum, 2-5 parts of bifidobacterium animalis subspecies V9 microbial inoculums, Lactobacillus plantarum
2-5 parts of P-8 microbial inoculums, galactooligosaccharide 20-30 parts, glucose 10-20 parts, microcrystalline cellulose 10-20 parts, soluble soybean polysaccharide
0.1-0.5 parts.
It is highly preferred that the mixing probiotic tablet, is mainly prepared by the raw material of following parts by weight:Lactobacillus acidophilus
3 parts of KT-A1 microbial inoculums, 3 parts of Lactobacillus casei Zhang microbial inoculum, 3 parts of bifidobacterium animalis subspecies V9 microbial inoculums, Lactobacillus plantarum P-8
3 parts of microbial inoculum, 25 parts of galactooligosaccharide, 15 parts of glucose, 15 parts of microcrystalline cellulose, 0.3 part of soluble soybean polysaccharide.
Further, the lactobacillus acidophilus KT-A1 microbial inoculums, Lactobacillus casei Zhang microbial inoculum, bifidobacterium animalis are sub-
The preparation of V9 microbial inoculums and Lactobacillus plantarum P-8 microbial inoculums is planted, is comprised the following steps:
Lactobacillus acidophilus KT-A1, Lactobacillus casei Zhang, the bifidobacterium animalis subspecies after ring activation are taken respectively
V9 and the inclined-plane thalline of Lactobacillus plantarum P-8 bacterium, are each seeded in MRS culture mediums respectively, at mutually synthermal 33~37 DEG C,
18~24h is cultivated under the conditions of 50~100rpm of same rotational speed, primary seed solution is respectively obtained;Cultured primary seed solution is pressed
Inoculum concentration 3%~10% (v/v) to be transferred carry out re-activation into MRS culture mediums again, and two grades of kinds are obtained after 18~24h of soak time
Sub- liquid;Secondary seed solution is each linked into different fermentation tanks respectively according to identical inoculum concentration 3%~10% (v/v) respectively to train
Support in base, temperature is 33~37 DEG C, and rotating speed is 50~100rpm, and ventilation is 0.3~1L/min, full adjustment of fermenting
Zymotic fluid same pH is to cultivate 8~12 hours under the conditions of 5.6~6.2, respectively obtains final lactobacillus acidophilus KT-A1 fermentation
Liquid, final Lactobacillus casei Zhang zymotic fluid, final bifidobacterium animalis subspecies V9 zymotic fluids and final Lactobacillus plantarum
P-8 zymotic fluids, respectively through 5000~12000rpm, 5~15min is collected by centrifugation thalline to the above-mentioned final zymotic fluid that will be obtained;
To through the lactobacillus acidophilus KT-A1 after centrifugation, Lactobacillus casei Zhang, bifidobacterium animalis subspecies V9 and
Compare 1 according to respective thalline and protective agent solution quality respectively in the thalline of Lactobacillus plantarum:The ratio addition protective agent of (5~10)
Solution, mixes and obtains bacteria suspension, and the bacteria suspension is freeze-dried, respectively obtains lactobacillus acidophilus KT-A1, Lactobacillus casei
The lyophilized microbial inoculum of Zhang, bifidobacterium animalis subspecies V9 and Lactobacillus plantarum.
Further, the lactobacillus acidophilus KT-A1, Lactobacillus casei Zhang, bifidobacterium animalis subspecies V9 and
The respective viable count of the zymotic fluid of Lactobacillus plantarum reaches 1010More than CFU/ml.
Further, the lactobacillus acidophilus KT-A1, Lactobacillus casei Zhang, bifidobacterium animalis subspecies V9 and
The respective total viable count of lyophilized microbial inoculum of Lactobacillus plantarum reaches 2 × 1011More than CFU/g.
The fermentation tank culture medium (g/L):Sucrose 50~80, dusty yeast 20~40, soy peptone 8~20,
MgSO4.7H2O 1.5~2.0, MnSO4.5H2O 0.08~0.12, Tween-80 0.8~1.0, balance of water, pH7.0.
The formula of the protection agent solution is following (g/L):Skimmed milk 10-15, trehalose 8~15, balance of distilled water.
Low temperature packaging technique preparation method another object of the present invention is to provide above-mentioned mixing probiotic tablet, including
Following steps:
Raw material mixes:By lactobacillus acidophilus KT-A1 microbial inoculums, Lactobacillus casei Zhang microbial inoculum, bifidobacterium animalis subspecies
V9 microbial inoculums, Lactobacillus plantarum P-8 microbial inoculums and galactooligosaccharide, glucose, microcrystalline cellulose, soluble soybean polysaccharide are multiple in proportion
With mixing, using 3 D multi-directional movement mixer, fully mixed under conditions of rotating speed is 5-15rpm, incorporation time 10-
30min, obtains probiotics compound;
Compressing tablet:The probiotics compound is used into tabletting machine, piece weight 0.7-0.9g/ pieces, hardness reaches 7N/cm2
More than;Obtain sheet probiotics compound;
Low temperature is coated:The sheet probiotics compound is carried out by low temperature bag using soluble soybean polysaccharide by seed-coating machine
Clothing, is coated 45-55 DEG C of temperature, Coating times 2-4 hours, that is, obtains mixing probiotic tablet.
Preferably, the low temperature packaging technique preparation method of the mixing probiotic tablet, comprises the following steps:
Raw material mixes:By lactobacillus acidophilus KT-A1 microbial inoculums, Lactobacillus casei Zhang microbial inoculum, bifidobacterium animalis subspecies
V9 microbial inoculums, Lactobacillus plantarum P-8 microbial inoculums are compounded and mixed in proportion with galactooligosaccharide, glucose, microcrystalline cellulose, using three-dimensional
Mixers with Multi-direction Movement, fully mixes under conditions of rotating speed is 10rpm, and incorporation time 20min obtains probiotics compound;
Compressing tablet:The probiotics compound is used into tabletting machine, piece weight 0.7-0.9g/ pieces, hardness 8N/cm2,;Obtain
Sheet probiotics compound;
Low temperature is coated:The sheet probiotics compound is carried out by low temperature bag using soluble soybean polysaccharide by seed-coating machine
Clothing, is coated temperature 50 C, and Coating times 3 hours obtain mixing probiotic tablet.
Further, the total viable count in the mixing probiotic tablet reaches 5 × 109More than CFU/g.
The lactobacillus acidophilus KT-A1, is preserved in Chinese microorganism strain preservation conservator on the 8th in September in 2016
Can common micro-organisms center (abbreviation CGMCC), culture presevation number:CGMCC No.12951, preservation address is:Court of city of BeiJing, China
The institute 3 of positive area's North Star West Road 1, Institute of Microorganism, Academia Sinica, postcode:100101, Classification And Nomenclature is lactobacillus acidophilus
(Lactobacillus acidophilus)。
The Lactobacillus casei zhang, is preserved in Chinese microorganism strain preservation management committee on November 18th, 2011
Member's meeting common micro-organisms center (abbreviation CGMCC), preserving number is CGMCC No.5469, and preservation address is:City of BeiJing, China is exposed to the sun
The institute 3 of area North Star West Road 1, Institute of Microorganism, Academia Sinica, postcode:100101, Classification And Nomenclature is Lactobacillus casei
(Lactobacillus casei).The bacterial strain is to be isolated within 2001 being sent out naturally on In Xilingol League In Inner Mongolia Zhenglan Banner grassland
One plant in ferment koumiss (Komiss) Lactobacillus casei with excellent probiotic properties.
The bifidobacterium animalis subspecies V9, is preserved in Chinese microorganism strain preservation pipe on November 18th, 2011
Reason committee common micro-organisms center (abbreviation CGMCC), preserving number is CGMCC No.5470, and preservation address is:City of BeiJing, China
The institute 3 of Chaoyang District North Star West Road 1, Institute of Microorganism, Academia Sinica, postcode:100101, Classification And Nomenclature is animal bifid
Bacillus breast subspecies (Bifidobacterium animalis subsp.lactis).The bacterial strain is to be isolated from the Inner Mongol in 2005
One plant on grassland in the healthy Mongols children's enteron aisle bifidobacterium animalis subspecies with excellent probiotic properties.
The Lactobacillus plantarum P-8, was preserved in Chinese microorganism strain preservation conservator on 06 28th, 2012
Meeting common micro-organisms center (abbreviation CGMCC), preserving number is CGMCC No.6312, and preservation address is:City of BeiJing, China Chaoyang District
The institute 3 of North Star West Road 1, Institute of Microorganism, Academia Sinica, postcode:100101, Classification And Nomenclature is Lactobacillus plantarum
(Lactobacillus plantarum).The bacterial strain is 2003 from the natural fermented sourdough in the herdsman family of Inner Mongolia Autonomous Region
One plant for being separated in milk and being filtered out has the lactic bacteria strain of excellent probiotic properties.
Beneficial effect:
The present invention is individually separated the L.acidophilus KT- from cultured milk, healthy children enteron aisle and koumiss sample
A1, L.plantarum P-8, B.lactis V9 and L.casei Zhang probiotic strains prepare mixing probiotic tablet, above-mentioned
Probiotics has excellent anti-gastrointestinal tract digestive juice tolerance;Improve the ability of human enteric bacteria group structure, improve body and disappear
Change absorptivity;Regulation blood lipid metabolism, there is Conservative restoration to act on hyperlipemia liver, strengthen antioxidant ability of organism;To machine
Body is immune to have adjustment effect;The intestinal irritable syndromes such as diarrhoea, constipation, stomachache, abdominal distension are alleviated in effectively prevention;Effective prevention of tumor
The effects such as growth and the generation of type II diabetes.
The mixing probiotic tablet prepared by low temperature packaging technique not only avoid what probiotics was caused in film-making process
Thalline loses, and greatly increases storage-stable of the probiotics in shelf life, is preserved 5 months at 37 DEG C,
The total viable count of probiotics keeps being not less than 5 × 10 in product9CFU/g;Product piece weight 0.7-0.9g/ pieces, hardness reaches 7N/cm2,
Surface is smooth, does not have dry linting phenomenon.
Brief description of the drawings
Below in conjunction with the accompanying drawings and specific embodiment the invention will be further described:
Accompanying drawing 1 is that experimental group compares with mixing probiotic tablet hardness in control group;
Accompanying drawing 2 is that mixing probiotic tablet preserves the change of total number of live bacteria of probiotics in 5 months at 37 DEG C.
Specific embodiment
The present invention is described below by specific embodiment.Unless stated otherwise, technological means used in the present invention
It is method known in those skilled in the art.In addition, embodiment is interpreted as illustrative, it is not intended to limit the present invention
Scope, the spirit and scope of the invention are limited only by the claims that follow.To those skilled in the art, without departing substantially from this
On the premise of invention spirit and scope, the various changes that are carried out to the material component and consumption in these embodiments or change
Belong to protection scope of the present invention.
Embodiment 1:The fermentation preparation of four clock microbial inoculums
Lactobacillus acidophilus KT-A1 microbial inoculums, Lactobacillus casei Zhang microbial inoculum, bifidobacterium animalis subspecies V9 microbial inoculums and
Prepared by the fermentation of Lactobacillus plantarum P-8 microbial inoculums, comprise the following steps:
Lactobacillus acidophilus KT-A1, Lactobacillus casei Zhang, the bifidobacterium animalis subspecies after ring activation are taken respectively
V9 and the inclined-plane thalline of Lactobacillus plantarum P-8 bacterium, are each seeded to MRS culture mediums respectively, in mutually synthermal 37 DEG C, identical turn
18h is cultivated under the conditions of fast 100rpm, primary seed solution is respectively obtained;Cultured primary seed solution is pressed into inoculum concentration 3% (v/v)
Transfer again and carry out re-activation into MRS culture mediums, secondary seed solution is obtained after soak time 18h;Secondary seed solution is pressed respectively
Photograph is each accessed in the 5L fermentation tanks of 3L fermentation tank culture mediums respectively with inoculum concentration 3% (v/v), and temperature is 37 DEG C, is turned
Speed is 100rpm, and ventilation is 0.3L/min, and fermentation full adjustment zymotic fluid same pH is that culture 10 is small under the conditions of 6.2
When, respectively obtain final lactobacillus acidophilus KT-A1 zymotic fluids, final Lactobacillus casei Zhang zymotic fluid, final animal bifid bar
Bacterium breast subspecies V9 zymotic fluids and final Lactobacillus plantarum P-8 zymotic fluids, the above-mentioned final zymotic fluid that will be obtained are passed through respectively
8000rpm, 5min are collected by centrifugation thalline;
To through the lactobacillus acidophilus KT-A1 after centrifugation, Lactobacillus casei Zhang, bifidobacterium animalis subspecies V9 and
Compare 1 according to respective thalline and protective agent solution quality respectively in the thalline of Lactobacillus plantarum:5 ratio addition protection agent solution,
Mix and obtain bacteria suspension, the bacteria suspension is freeze-dried, respectively obtain lactobacillus acidophilus KT-A1, Lactobacillus casei
The lyophilized microbial inoculum of Zhang, bifidobacterium animalis subspecies V9 and Lactobacillus plantarum.
Lactobacillus acidophilus KT-A1, Lactobacillus casei Zhang, bifidobacterium animalis subspecies V9 and Lactobacillus plantarum
The respective viable count of zymotic fluid reaches 1010More than CFU/ml.
Lactobacillus acidophilus KT-A1, Lactobacillus casei Zhang, bifidobacterium animalis subspecies V9 and Lactobacillus plantarum
The lyophilized respective total viable count of microbial inoculum reaches 2 × 1011More than CFU/g.
Fermentation tank culture medium (g/L):Sucrose 50~80, dusty yeast 20~40, soy peptone 8~20, MgSO4﹒ 7H2O
1.5~2.0, MnSO4.5H2O 0.08~0.12, Tween-80 0.8~1.0, balance of water, pH 7.0;
Protect the formula of agent solution following (g/L):Skimmed milk 10-15, trehalose 8~15, balance of distilled water.
Lactobacillus acidophilus KT-A1 microbial inoculums, Lactobacillus casei Zhang microbial inoculum, animal bifidobacteria used by example 2 below -5
Newborn subspecies V9 microbial inoculums and Lactobacillus plantarum P-8 microbial inoculums are prepared by embodiment 1.
Embodiment 2:Mix the preparation of probiotic tablet
One kind mixing probiotic tablet, is mainly prepared by the raw material of following parts by weight:Lactobacillus acidophilus KT-A1 microbial inoculums 2
It is part, 2 parts of Lactobacillus casei Zhang microbial inoculum, 2 parts of bifidobacterium animalis subspecies V9 microbial inoculums, 2 parts of Lactobacillus plantarum P-8 microbial inoculums, low
10 parts of poly- galactolipin, 10 parts of glucose, 10 parts of microcrystalline cellulose, 0.1 part of soluble soybean polysaccharide.
Low temperature packaging technique preparation method another object of the present invention is to provide above-mentioned mixing probiotic tablet, including
Following steps:
Raw material mixes:By lactobacillus acidophilus KT-A1 microbial inoculums, Lactobacillus casei Zhang microbial inoculum, bifidobacterium animalis subspecies
V9 microbial inoculums, Lactobacillus plantarum P-8 microbial inoculums are compounded and mixed in proportion with galactooligosaccharide, glucose, microcrystalline cellulose, using three-dimensional
Mixers with Multi-direction Movement, fully mixes under conditions of rotating speed is 5rpm, and incorporation time 10min obtains probiotics compound;
Compressing tablet:The probiotics compound is used into tabletting machine, piece weight 0.7g/ pieces, hardness 7.7N/cm2,;Obtain piece
Shape probiotics compound;
Low temperature is coated:The sheet probiotics compound is carried out by low temperature bag using soluble soybean polysaccharide by seed-coating machine
Clothing, is coated temperature 45 C, Coating times 2 hours.
Total viable count in the mixing probiotic tablet is 5.8 × 109CFU/g。
Embodiment 3;Mix the preparation of probiotic tablet
One kind mixing probiotic tablet, is mainly prepared by the raw material of following parts by weight:Lactobacillus acidophilus KT-A1 microbial inoculums 7
It is part, 7 parts of Lactobacillus casei Zhang microbial inoculum, 7 parts of bifidobacterium animalis subspecies V9 microbial inoculums, 7 parts of Lactobacillus plantarum P-8 microbial inoculums, low
40 parts of poly- galactolipin, 30 parts of glucose, 30 parts of microcrystalline cellulose, 0.7 part of soluble soybean polysaccharide.
Low temperature packaging technique preparation method another object of the present invention is to provide above-mentioned mixing probiotic tablet, including
Following steps:
Raw material mixes:By lactobacillus acidophilus KT-A1 microbial inoculums, Lactobacillus casei Zhang microbial inoculum, bifidobacterium animalis subspecies
V9 microbial inoculums, Lactobacillus plantarum P-8 microbial inoculums are compounded and mixed in proportion with galactooligosaccharide, glucose, microcrystalline cellulose, using three-dimensional
Mixers with Multi-direction Movement, fully mixes under conditions of rotating speed is 15rpm, and incorporation time 30min obtains probiotics compound;
Compressing tablet:The probiotics compound is used into tabletting machine, piece weight 0.9g/ pieces, hardness 9N/cm2,;Obtain sheet
Probiotics compound;
Low temperature is coated:The sheet probiotics compound is carried out by low temperature bag using soluble soybean polysaccharide by seed-coating machine
Clothing, is coated 55 DEG C of temperature, Coating times 4 hours.
Total viable count in the mixing probiotic tablet is 6.9 × 109CFU/g。
Embodiment 4;Mix the preparation of probiotic tablet
One kind mixing probiotic tablet, is mainly prepared by the raw material of following parts by weight:Lactobacillus acidophilus KT-A1 microbial inoculums
3.5 parts, 3.5 parts of Lactobacillus casei Zhang microbial inoculum, 3.5 parts of bifidobacterium animalis subspecies V9 microbial inoculums, Lactobacillus plantarum P-8 bacterium
3.5 parts of agent, 25 parts of galactooligosaccharide, 15 parts of glucose, 15 parts of microcrystalline cellulose, 0.3 part of soluble soybean polysaccharide.
Mix the low temperature packaging technique preparation method of probiotic tablet, comprise the following steps:
Raw material mixes:By lactobacillus acidophilus KT-A1 microbial inoculums, Lactobacillus casei Zhang microbial inoculum, bifidobacterium animalis subspecies
V9 microbial inoculums, Lactobacillus plantarum P-8 microbial inoculums are compounded and mixed in proportion with galactooligosaccharide, glucose, microcrystalline cellulose, using three-dimensional
Mixers with Multi-direction Movement, fully mixes under conditions of rotating speed is 10rpm, and incorporation time 20min obtains probiotics compound;
Compressing tablet:The probiotics compound is used into tabletting machine, piece weight 0.8g/ pieces, hardness 7.96N/cm2,;Obtain
Sheet probiotics compound;
Low temperature is coated:The sheet probiotics compound is carried out by low temperature bag using soluble soybean polysaccharide by seed-coating machine
Clothing, is coated temperature 50 C, Coating times 3 hours.
Total viable count in mixing probiotic tablet is not less than 6.4 × 109CFU/g。
Embodiment 5:Mix the preparation of probiotic tablet
One kind mixing probiotic tablet, is mainly prepared by the raw material of following parts by weight:Lactobacillus acidophilus KT-A1 microbial inoculums 5
It is part, 5 parts of Lactobacillus casei Zhang microbial inoculum, 5 parts of bifidobacterium animalis subspecies V9 microbial inoculums, 5 parts of Lactobacillus plantarum P-8 microbial inoculums, low
30 parts of poly- galactolipin, 20 parts of glucose, 20 parts of microcrystalline cellulose, 0.5 part of soluble soybean polysaccharide.
Low temperature packaging technique preparation method another object of the present invention is to provide above-mentioned mixing probiotic tablet, including
Following steps:
Raw material mixes:By lactobacillus acidophilus KT-A1 microbial inoculums, Lactobacillus casei Zhang microbial inoculum, bifidobacterium animalis subspecies
V9 microbial inoculums, Lactobacillus plantarum P-8 microbial inoculums are compounded and mixed in proportion with galactooligosaccharide, glucose, microcrystalline cellulose, using three-dimensional
Mixers with Multi-direction Movement, fully mixes under conditions of rotating speed is 10rpm, and incorporation time 25min obtains probiotics compound;
Compressing tablet:Tabletting machine, piece is used to weigh 0.85g/ pieces the probiotics compound, hardness is 8.4N/cm2,;Obtain
Obtain sheet probiotics compound;
Low temperature is coated:The sheet probiotics compound is carried out by low temperature bag using soluble soybean polysaccharide by seed-coating machine
Clothing, is coated temperature 50 C, Coating times 3 hours.
Total viable count in the mixing probiotic tablet is not less than 6.6 × 109CFU/g。
Embodiment 6:Part antagonistic property and the tolerance test of lactobacillus acidophilus KT-La9
Lactobacillus acidophilus KT-La9 is isolated from the Feed Sample of spontaneous fermentation, can effectively suppress human body intestinal canal large intestine bar
The growth and breeding of the pathogenic bacteria such as bacterium, staphylococcus aureus, Shigella, salmonella, unit cell listeria spp, tolerance are dynamic
The acidity and alkaline environment of thing intestines and stomach, survive and are colonized in human body intestinal canal.
Antagonistic property is tested:
Lactobacillus acidophilus KT-A1 bacterial strains are carried out after 37 DEG C of culture 24h in MRS fluid nutrient mediums under the conditions of 12000 turns
Centrifugation 15min, the supernatant for obtaining obtains cell-free extract through filtration sterilization, and then preservation is stand-by at -80 DEG C of temperature;
Prepare to carry pathogenic bacteria flat board:20mL sterilizing MRS agar mediums are cooled to 45 DEG C, then with 200 μ L105-
106CFU/mL pathogenic bacteria bacteria suspension (Escherichia coli, staphylococcus aureus, Shigella, salmonella, unit cell Listeria
Bacterium) mixing on agar plate is poured on together;After solidification to be cooled, the hole of diameter 0.8cm is got on flat board using card punch;Often
Individual hole adds the 100 above-mentioned cell-free extracts of μ L, is spread in 4 DEG C of refrigerators of temperature and cultivated at 37 DEG C of temperature after 12h
24h;After obvious inhibition zone to appear inhibition zone diffusion diameter mm is recorded using slide measure.
The part antagonistic property (inhibition zone size) and tolerance of lactobacillus acidophilus KT-La9 see the table below.
The part antagonistic property (inhibition zone size) and tolerance of the lactobacillus acidophilus KT-La9 of table 1
Embodiment 7;Mix the hardness and viable bacteria stability test of probiotic tablet
Control group is commercially available common mixing probiotic tablet, and test group is the mixing probiotics prepared using embodiment 4
Tablet.
Mixing probiotic tablet is prepared according to the present embodiment 4, the thalline that probiotics is caused in film-making process is not only avoid
Loss, and storage-stable of the probiotics in shelf life is greatly increased, preserved 5 months at 37 DEG C, product
The middle total viable count of probiotics keeps being not less than 5 × 109CFU/g;Product piece weight 0.7-0.9g/ pieces.As can be seen from Table 2, mix
Probiotic tablet hardness reaches 7N/cm2More than, and compared with control group, surface is smooth, does not have dry linting phenomenon.
The experimental group of table 2 compares with probiotic tablet hardness in control group
Control group | 7.51N/cm2 |
Test group | 7.96N/cm2 |
Table 3 mixes probiotic tablet and preserves the change of total number of live bacteria of probiotics in 5 months at 37 DEG C
Packet | Initially (0 month) | 1 month | 3 months | 5 months |
Control group | 6.02×109CFU/g | 5.41×109CFU/g | 4.32×109CFU/g | 3.52×109CFU/g |
Test group | 6.02×109CFU/g | 5.86×109CFU/g | 5.53×109CFU/g | 5.14×109CFU/g |
By table 3 it is apparent that test group is coated the mix bacterium agent for preparing in initial placement 1 month by low temperature
When, its thalline vigor is significantly higher by 0.43 × 10 than control group9CFU/g.With the extension of shelf life, after placing 3 months,
The thalline vigor of test group is declined slightly, and more initial number of live bacteria of probiotics only have dropped 8.86%, but still keeps bacterium higher
Vitality of subject, number of live bacteria of probiotics still keeps level higher, and control group is by after the placement of 3 months, its probiotics viable bacteria
Number has significant downward trend, and 1.7 × 10 are have dropped altogether9CFU/g, more initial number of live bacteria of probiotics has been remarkably decreased 28.24%,
Thalline vigor has significantly downward trend, and the thalline vigor decreasing ratio compared with test group significantly improves 19.38%.
Place 5 months after, the thalline vigor of test group is declined slightly, and fall is not obvious compared with control group, only under
Drop 0.88 × 109CFU/g, and the number of live bacteria of probiotics of control group then has significantly more downward trend, it is notable compared with initial value
Have dropped 2.5 × 109CFU/g。
It is to be apparent that by Fig. 2, probiotic tablet is by the placement of 1,3,5 months, the probiotics viable bacteria of test group
Number compares control group, is declined slightly, and fall off rate is more slow, has more significant with the bacterial strain vigor that this illustrates test group
Stability.And compared to test group, the number of live bacteria of probiotics of control group has significant downward trend, more initial number of live bacteria of probiotics
It has been remarkably decreased 41.52%, the probiotic tablet of courseware control group almost loses by the placement of 5 months, its number of live bacteria of probiotics
Half is lost, spawn activity also almost only deposits the half of initial probiotics bacterium vigor.
It should be noted that:Embodiment of the present invention 2-3, the 5 mixing probiotic tablets for preparing equally are imitated with above-mentioned experiment
Really, it is between each embodiment and little with above-mentioned experiment effect otherness.
Embodiment 8 mixes tolerance of the probiotic tablet in inside of human body
Control group is commercially available common mixing probiotic tablet, and test group is the mixing probiotics prepared using embodiment 4
Tablet.
Table 4 mixes probiotic tablet to be tested in the tolerance of human body
It should be noted that:Embodiment of the present invention 2-3, the 5 mixing probiotic tablets for preparing equally are imitated with above-mentioned experiment
Really, it is between each embodiment and little with above-mentioned experiment effect otherness.
Claims (10)
1. a kind of mixing probiotic tablet, is mainly prepared by the raw material of following parts by weight:Lactobacillus acidophilus KT-A1 microbial inoculums 2-7
Part, 2-7 parts of Lactobacillus casei Zhang microbial inoculum, 2-7 parts of bifidobacterium animalis subspecies V9 microbial inoculums, Lactobacillus plantarum P-8 microbial inoculums 2-
7 parts, galactooligosaccharide 10-40 parts, glucose 10-30 parts, microcrystalline cellulose 10-30 parts, soluble soybean polysaccharide 0.1-0.7
Part;The lactobacillus acidophilus KT-A1 preserving numbers are CGMCC No.12951, and the Lactobacillus casei Zhang preserving number is CGMCC
No.5469, the bifidobacterium animalis subspecies V9 preserving numbers are CGMCC No.5470, the Lactobacillus plantarum P-8 preserving numbers
It is CGMCC No.6312.
2. one kind as claimed in claim 1 mixes probiotic tablet, it is characterised in that:The mixing probiotic tablet, mainly
Prepared by the raw material of following parts by weight:It is 2-5 parts of lactobacillus acidophilus KT-A1 microbial inoculums, 2-5 parts of Lactobacillus casei Zhang microbial inoculum, dynamic
2-5 parts of thing Bifidobacterium lactis spp V9 microbial inoculums, 2-5 parts of Lactobacillus plantarum P-8 microbial inoculums, galactooligosaccharide 20-30 parts, glucose
10-20 parts, microcrystalline cellulose 10-20 parts, soluble soybean polysaccharide 0.1-0.5 parts.
3. one kind as claimed in claim 1 mixes probiotic tablet, it is characterised in that:The mixing probiotic tablet, mainly
Prepared by the raw material of following parts by weight:3 parts of lactobacillus acidophilus KT-A1 microbial inoculums, 3 parts of Lactobacillus casei Zhang microbial inoculum, animal are double
3 parts of discrimination bacillus breast subspecies V9 microbial inoculums, 3 parts of Lactobacillus plantarum P-8 microbial inoculums, 25 parts of galactooligosaccharide, 15 parts of glucose, microcrystalline cellulose
Plain 15 parts, 0.3 part of soluble soybean polysaccharide.
4. one kind as claimed in claim 1 mixes probiotic tablet, it is characterised in that:The lactobacillus acidophilus KT-A1 microbial inoculums,
The preparation of Lactobacillus casei Zhang microbial inoculum, bifidobacterium animalis subspecies V9 microbial inoculums and Lactobacillus plantarum P-8 microbial inoculums, including
Following steps:
Take respectively a ring activation after lactobacillus acidophilus KT-A1, Lactobacillus casei Zhang, bifidobacterium animalis subspecies V9 with
And the inclined-plane thalline of Lactobacillus plantarum P-8 bacterium, each it is seeded to respectively in MRS culture mediums, it is identical at mutually synthermal 33~37 DEG C
18~24h is cultivated under the conditions of 50~100rpm of rotating speed, primary seed solution is respectively obtained;By cultured primary seed solution by inoculation
3%~10% (v/v) of amount to be transferred carry out re-activation into MRS culture mediums again, and secondary seed is obtained after 18~24h of soak time
Liquid;Secondary seed solution is each linked into different fermentation tank cultures respectively according to identical inoculum concentration 3%~10% (v/v) respectively
In base, temperature is 33~37 DEG C, and rotating speed is 50~100rpm, and ventilation is 0.3~1L/min, fermentation full adjustment hair
Zymotic fluid same pH be 5.6~6.2 under the conditions of cultivate 8~12 hours, respectively obtain final lactobacillus acidophilus KT-A1 zymotic fluids,
Final Lactobacillus casei Zhang zymotic fluid, final bifidobacterium animalis subspecies V9 zymotic fluids and final Lactobacillus plantarum P-8
Zymotic fluid, respectively through 5000~12000rpm, 5~15min is collected by centrifugation thalline to the above-mentioned final zymotic fluid that will be obtained;
To through the lactobacillus acidophilus KT-A1 after centrifugation, Lactobacillus casei Zhang, bifidobacterium animalis subspecies V9 and plant
Compare 1 according to respective thalline and protective agent solution quality respectively in the thalline of lactobacillus:The ratio addition protective agent of (5~10) is molten
Liquid, mixes and obtains bacteria suspension, and the bacteria suspension is freeze-dried, respectively obtains lactobacillus acidophilus KT-A1, Lactobacillus casei
The lyophilized microbial inoculum of Zhang, bifidobacterium animalis subspecies V9 and Lactobacillus plantarum.
5. one kind as claimed in claim 4 mixes probiotic tablet, it is characterised in that:The lactobacillus acidophilus KT-A1, cheese
The respective viable count of the zymotic fluid of lactobacillus Zhang, bifidobacterium animalis subspecies V9 and Lactobacillus plantarum reaches
1010More than CFU/ml.
6. one kind as claimed in claim 4 mixes probiotic tablet, it is characterised in that:The lactobacillus acidophilus KT-A1, cheese
The respective total viable count of lactobacillus Zhang, the lyophilized microbial inoculum of bifidobacterium animalis subspecies V9 and Lactobacillus plantarum reaches 2
×1011More than CFU/g.
7. one kind as claimed in claim 4 mixes probiotic tablet, it is characterised in that:The fermentation tank culture medium (g/L):Sugarcane
Sugar 50~80, dusty yeast 20~40, soy peptone 8~20, MgSO4.7H2O 1.5~2.0, MnSO4.5H2O 0.08~
0.12, Tween-80 0.8~1.0, balance of water, pH7.0;The formula of the protection agent solution is following (g/L):Skimmed milk 10-
15, trehalose 8~15, balance of distilled water.
8. the low temperature packaging technique preparation method of the mixing probiotic tablet as described in claim 1-7 is any, including following step
Suddenly:
Raw material mixes:By lactobacillus acidophilus KT-A1 microbial inoculums, Lactobacillus casei Zhang microbial inoculum, bifidobacterium animalis subspecies V9 bacterium
Agent, Lactobacillus plantarum P-8 microbial inoculums and galactooligosaccharide, glucose, microcrystalline cellulose, soluble soybean polysaccharide compound mixed in proportion
Close, using 3 D multi-directional movement mixer, fully mixed under conditions of rotating speed is 5-15rpm, incorporation time 10-30min is obtained
Obtain probiotics compound;
Compressing tablet:The probiotics compound is used into tabletting machine, piece weight 0.7-0.9g/ pieces, hardness reaches 7N/cm2More than;
Obtain sheet probiotics compound;
Low temperature is coated:The sheet probiotics compound is carried out by low temperature coating using soluble soybean polysaccharide by seed-coating machine,
It is coated 45-55 DEG C of temperature, Coating times 2-4 hours, that is, obtains mixing probiotic tablet.
9. the low temperature packaging technique preparation method of probiotic tablet is mixed as claimed in claim 8, it is characterised in that:Including such as
Lower step:
Raw material mixes:By lactobacillus acidophilus KT-A1 microbial inoculums, Lactobacillus casei Zhang microbial inoculum, bifidobacterium animalis subspecies V9 bacterium
Agent, Lactobacillus plantarum P-8 microbial inoculums are compounded and mixed in proportion with galactooligosaccharide, glucose, microcrystalline cellulose, using 3 D multi-directional
Movement mixer, fully mixes under conditions of rotating speed is 10rpm, and incorporation time 20min obtains probiotics compound;
Compressing tablet:The probiotics compound is used into tabletting machine, piece weight 0.7-0.9g/ pieces, hardness 8N/cm2,;Obtain sheet
Probiotics compound;
Low temperature is coated:The sheet probiotics compound is carried out by soluble soybean polysaccharide by low temperature coating by seed-coating machine, is wrapped
Clothing temperature 50 C, Coating times 3 hours obtain mixing probiotic tablet.
10. the low temperature packaging technique preparation method of probiotic tablet is mixed as claimed in claim 8, it is characterised in that:It is described
Total viable count in mixing probiotic tablet reaches 5 × 109More than CFU/g.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611077462.9A CN106690327A (en) | 2016-11-30 | 2016-11-30 | Mixed probiotic tablets and low-temperature coating preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611077462.9A CN106690327A (en) | 2016-11-30 | 2016-11-30 | Mixed probiotic tablets and low-temperature coating preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106690327A true CN106690327A (en) | 2017-05-24 |
Family
ID=58935122
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611077462.9A Pending CN106690327A (en) | 2016-11-30 | 2016-11-30 | Mixed probiotic tablets and low-temperature coating preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106690327A (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108004189A (en) * | 2018-01-18 | 2018-05-08 | 北京科拓恒通生物技术股份有限公司 | A kind of compound probiotic lactic acid bacteria powder and preparation method and application |
CN108118012A (en) * | 2018-01-19 | 2018-06-05 | 南昌大学 | Coordinate compound probiotic microbial inoculum, the preparation method and the usage of tumor operation treatment |
CN108114004A (en) * | 2018-01-19 | 2018-06-05 | 南昌大学 | Compound probiotic microbial inoculum for carrying out immunization therapy and preparation method thereof can be directly administered |
CN108125902A (en) * | 2018-01-08 | 2018-06-08 | 北京科拓恒通生物技术股份有限公司 | A kind of probiotic composition, facial treatment essence liquid and facial mask and preparation method thereof |
CN108130297A (en) * | 2018-01-19 | 2018-06-08 | 南昌大学 | Coordinate compound probiotic microbial inoculum, the preparation method and the usage of CART cell therapies |
CN108165510A (en) * | 2018-01-19 | 2018-06-15 | 南昌大学 | It is a kind of for compound probiotic microbial inoculum of neoplasm targeted therapy and preparation method thereof |
CN108741090A (en) * | 2018-08-28 | 2018-11-06 | 安徽谷益生物科技有限公司 | A kind of compound probiotic functional food inhibiting helicobacter pylori |
CN110432495A (en) * | 2018-05-03 | 2019-11-12 | 内蒙古伊利实业集团股份有限公司 | A kind of probiotics preparation and preparation method thereof of acidproof resistance to bile salt |
CN110882281A (en) * | 2019-11-30 | 2020-03-17 | 江苏艾兰得营养品有限公司 | Probiotic enteric-coated tablet and preparation method thereof |
CN111575202A (en) * | 2020-05-19 | 2020-08-25 | 北京科拓恒通生物技术股份有限公司 | Lactobacillus casei for prevention and adjuvant therapy of type II diabetes and application thereof |
CN113005067A (en) * | 2021-03-31 | 2021-06-22 | 盐城维康生物科技有限公司 | Multifunctional composite probiotic preparation and preparation method thereof |
CN113558244A (en) * | 2020-04-28 | 2021-10-29 | 江中药业股份有限公司 | Probiotic composition and preparation method thereof |
CN114073313A (en) * | 2021-11-19 | 2022-02-22 | 北京局气网络技术有限公司 | Compound oligosaccharide active bacterium medlar tablet and preparation method thereof |
CN115486540A (en) * | 2021-08-25 | 2022-12-20 | 江中药业股份有限公司 | Probiotic herbal composition with antioxidant effect and preparation method thereof |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1431870A (en) * | 2000-05-11 | 2003-07-23 | 钟纺株式会社 | Compsns. contg. peptide and electrolyte excretion promoter and foods contg. same |
CN101637294A (en) * | 2009-08-26 | 2010-02-03 | 中国农业科学院饲料研究所 | Water-soluble soybean polysaccharide coating preservative |
CN102204679A (en) * | 2011-06-16 | 2011-10-05 | 高杰 | Quadruple bacterial tablets and preparation method thereof |
CN102864096A (en) * | 2012-04-18 | 2013-01-09 | 北京和美科盛生物技术有限公司 | Lactobacillus plantarum and preparation method thereof for high-density culture and freeze-drying bacteria powder |
CN103652089A (en) * | 2013-12-10 | 2014-03-26 | 华中农业大学 | Tea polysaccharide lozenge and preparation method thereof |
CN103893214A (en) * | 2014-03-28 | 2014-07-02 | 北京和美科盛生物技术有限公司 | Probiotics viable bacteria powder produced by whole oat solid-state mixed fermentation and preparation method of probiotics viable bacteria powder |
CN103898018A (en) * | 2014-03-28 | 2014-07-02 | 北京和美科盛生物技术有限公司 | High-density culture method of bifidobacterium lactis and preparation method of freeze-dried powder of bifidobacterium lactis |
CN105901741A (en) * | 2016-03-23 | 2016-08-31 | 江南大学 | Lead poison-relieving dietary supplement containing probiotics and plant extract |
-
2016
- 2016-11-30 CN CN201611077462.9A patent/CN106690327A/en active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1431870A (en) * | 2000-05-11 | 2003-07-23 | 钟纺株式会社 | Compsns. contg. peptide and electrolyte excretion promoter and foods contg. same |
CN101637294A (en) * | 2009-08-26 | 2010-02-03 | 中国农业科学院饲料研究所 | Water-soluble soybean polysaccharide coating preservative |
CN102204679A (en) * | 2011-06-16 | 2011-10-05 | 高杰 | Quadruple bacterial tablets and preparation method thereof |
CN102864096A (en) * | 2012-04-18 | 2013-01-09 | 北京和美科盛生物技术有限公司 | Lactobacillus plantarum and preparation method thereof for high-density culture and freeze-drying bacteria powder |
CN103652089A (en) * | 2013-12-10 | 2014-03-26 | 华中农业大学 | Tea polysaccharide lozenge and preparation method thereof |
CN103893214A (en) * | 2014-03-28 | 2014-07-02 | 北京和美科盛生物技术有限公司 | Probiotics viable bacteria powder produced by whole oat solid-state mixed fermentation and preparation method of probiotics viable bacteria powder |
CN103898018A (en) * | 2014-03-28 | 2014-07-02 | 北京和美科盛生物技术有限公司 | High-density culture method of bifidobacterium lactis and preparation method of freeze-dried powder of bifidobacterium lactis |
CN105901741A (en) * | 2016-03-23 | 2016-08-31 | 江南大学 | Lead poison-relieving dietary supplement containing probiotics and plant extract |
Non-Patent Citations (4)
Title |
---|
(德)伯格哈根(BURGHAGEN,M.M.著: "《食品化学》", 28 February 2008, 中国农业大学出版社 * |
侯秀英等主编: "《新编现代实用药剂学》", 31 July 2015, 西安交通大学出版社 * |
李凤林等: "《乳及发酵乳制品工艺学》", 31 July 2007, 中国轻工业出版社 * |
梁艺英编著: "《保健食品研发与审评》", 30 November 2012, 中国医药科技出版社 * |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019118346A (en) * | 2018-01-08 | 2019-07-22 | 北京科拓恒通生物技術股▲フェン▼有限公司 | Probiotics composition, skin care essence and mask as well as method for producing the same |
CN108125902A (en) * | 2018-01-08 | 2018-06-08 | 北京科拓恒通生物技术股份有限公司 | A kind of probiotic composition, facial treatment essence liquid and facial mask and preparation method thereof |
CN108004189A (en) * | 2018-01-18 | 2018-05-08 | 北京科拓恒通生物技术股份有限公司 | A kind of compound probiotic lactic acid bacteria powder and preparation method and application |
CN108118012A (en) * | 2018-01-19 | 2018-06-05 | 南昌大学 | Coordinate compound probiotic microbial inoculum, the preparation method and the usage of tumor operation treatment |
CN108114004A (en) * | 2018-01-19 | 2018-06-05 | 南昌大学 | Compound probiotic microbial inoculum for carrying out immunization therapy and preparation method thereof can be directly administered |
CN108130297A (en) * | 2018-01-19 | 2018-06-08 | 南昌大学 | Coordinate compound probiotic microbial inoculum, the preparation method and the usage of CART cell therapies |
CN108165510A (en) * | 2018-01-19 | 2018-06-15 | 南昌大学 | It is a kind of for compound probiotic microbial inoculum of neoplasm targeted therapy and preparation method thereof |
CN110432495A (en) * | 2018-05-03 | 2019-11-12 | 内蒙古伊利实业集团股份有限公司 | A kind of probiotics preparation and preparation method thereof of acidproof resistance to bile salt |
CN108741090A (en) * | 2018-08-28 | 2018-11-06 | 安徽谷益生物科技有限公司 | A kind of compound probiotic functional food inhibiting helicobacter pylori |
CN110882281A (en) * | 2019-11-30 | 2020-03-17 | 江苏艾兰得营养品有限公司 | Probiotic enteric-coated tablet and preparation method thereof |
CN113558244A (en) * | 2020-04-28 | 2021-10-29 | 江中药业股份有限公司 | Probiotic composition and preparation method thereof |
CN113558244B (en) * | 2020-04-28 | 2023-08-22 | 江中药业股份有限公司 | Probiotic composition and preparation method thereof |
CN111575202A (en) * | 2020-05-19 | 2020-08-25 | 北京科拓恒通生物技术股份有限公司 | Lactobacillus casei for prevention and adjuvant therapy of type II diabetes and application thereof |
CN113005067A (en) * | 2021-03-31 | 2021-06-22 | 盐城维康生物科技有限公司 | Multifunctional composite probiotic preparation and preparation method thereof |
CN115486540A (en) * | 2021-08-25 | 2022-12-20 | 江中药业股份有限公司 | Probiotic herbal composition with antioxidant effect and preparation method thereof |
CN114073313A (en) * | 2021-11-19 | 2022-02-22 | 北京局气网络技术有限公司 | Compound oligosaccharide active bacterium medlar tablet and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106690327A (en) | Mixed probiotic tablets and low-temperature coating preparation method thereof | |
CN103893214B (en) | Probiotics viable bacteria powder produced by whole oat solid-state mixed fermentation and preparation method of probiotics viable bacteria powder | |
CN1911118B (en) | Kefir mushroom freeze-dried powder, production method and use thereof | |
CN102174450B (en) | Lactobacillus plantarum for resisting helicobacter pylori infection and application thereof | |
CN103627656B (en) | A kind of clostridium butyricum and bacillus coagulans mixed culture solid state fermentation method | |
CN110141585A (en) | A kind of composite probiotics ferment microbial inoculum and preparation method thereof for adjusting intestinal flora | |
CN105779350B (en) | A kind of lactobacillus plantarum and application thereof of anti-Bacterium enteritidis infection | |
CN102586148A (en) | Plant lactobacillus capable of relieving lead toxicity and application thereof | |
CN101731511B (en) | Probiotic active product and preparation method thereof | |
CN104542977B (en) | A kind of health beverages and preparation method containing yam extract and bifidobacterium bifidum | |
CN101559082A (en) | Method for preparing probiotic preparation for reducing blood lipid and adjusting intestinal flora | |
CN109805232A (en) | Jujube three-stage probiotics fermention produces Low acid micro-ecological foods | |
CN106578064B (en) | Donkey-hide gelatin and lactic acid bacteria beverage and preparation method thereof | |
CN103911323A (en) | Bacillus licheniformis, bacillus subtilis and lactobacillus plantarum preparation and preparation | |
CN109929779A (en) | A kind of probiotics preparation and its preparation method and application containing biologically active peptide | |
CN104611256B (en) | A kind of microorganism lyophilized formulations and preparation method thereof | |
CN104212735A (en) | Poultry composite probiotic preparation and preparation method thereof | |
CN107988123A (en) | One plant has the lactobacillus plantarum for adjusting ampicillin induction enteric flora disturbance | |
CN109329699A (en) | A kind of probiotics seabuckthorn fruit mud jelly and preparation method thereof | |
CN110447722A (en) | A kind of fermented glutinous rice yoghurt premixed powder and preparation method thereof | |
CN105661230A (en) | Probiotic functional beverage and probiotic food prepared from Lens culinaris by fermentation | |
CN110122567A (en) | Composite fermentation cream with anti-oxidation function and preparation method thereof | |
CN108018248B (en) | Lactobacillus casei capable of regulating flora structural disorder caused by antibiotics | |
CN111635875A (en) | Bifidobacterium longum CZ70 and method for preparing live bacterial blackberry fruit pulp by using same | |
CN103952336A (en) | Bacillus licheniformis-Bacillus subtilis-Lactobacillus casei preparation and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20170522 Address after: 101407 Beijing city Huairou District Yanqi Economic Development Zone mangniu River Road No. 31, No. 1 -2 Applicant after: Beijing branch of Hengtong biotechnology Limited by Share Ltd Address before: 101407 Beijing city Huairou District Yanqi Economic Development Zone mangniu River Road No. 31 hospital Applicant before: BEIJING KETUO HENGTONG BIOTECHNOLOGY DEVELOPMENT CO., LTD. |
|
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170524 |